Global Spatial Genomics and Transcriptomics Market: Focus on Product Type, Sample Type, Workflow, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - Spatial Genomics and Transcriptomics
Market Segmentation
NanoString Technologies, Inc., S2 Genomics, Inc., Flagship Biosciences, Inc., Akoya Biosciences, Inc. RareCyte, Inc., IONpath, Inc., Fluidigm Corporation, 10x Genomics, Inc., Visikol, Inc., Miltenyi Biotec, and BioSpyder Technologies
Key Questions Answered in this Report:
BIS Research healthcare experts have found the spatial genomics and transcriptomics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 23.20% during the forecast period of 2020-2030. The market is driven by certain factors, which include the increasing prevalence of various types of genetic disorders, such as cancer, neurological disorder, and rare diseases, inciting the development of high-resolution multiplex assays and instruments, technological advancements in sequencing technologies, and significant research funding in the field of spatial-based technology for executing R&D exercises.
The market is favored by the development of spatial profiling-based solutions for visualization and analysis of tissue microenvironment, tumor biology, and tissue biomarker. The gradual increase in the prevalence of neurological disorders and rare diseases globally has furthered the spatial genomics and transcriptomics market.
Furthermore, several contract research organizations are focusing on the development of spatial profiling-based services, which enables simultaneous in-situ spatial analysis of multiple biomarkers proteins or more than a hundred mRNAs from single formalin-fixed paraffin-embedded (FFPE) tissue or frozen tissue section.
Within the research report, the market is segmented on the basis of product type, sample type, workflow, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, BioTechne Corporation has been a pioneer in this field and has been a significant competitor in this market.
Other key players in the market are NanoString Technologies, Inc., S2 Genomics, Inc., Flagship Biosciences, Inc., Akoya Biosciences, Inc. RareCyte, Inc., IONpath, Inc., Fluidigm Corporation, 10x Genomics, Inc., Visikol, Inc., Miltenyi Biotec, and BioSpyder Technologies.
On the basis of region, North America holds the largest share of spatial genomics and transcriptomics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Europe region is anticipated to grow at the fastest CAGR of 23.54% during the forecast period 2020-2030.
The market utilizes several technologies, such as barcoding, sequencing, mass cytometry, and microscopy, for the development of instruments and assay for spatial profiling of tissue section to gain an understanding of tissue microenvironment. Each solution offered by the leading players is the combination of next-generation omics tools for application in several clinical areas, such oncology, neurology, immunology, and pathology.
Market Report Coverage - Spatial Genomics and Transcriptomics
Market Segmentation
- Product Type – Kits and Assays, Instruments, Software, and Services
- Sample Type – Fresh Frozen Tissues, Fixed Frozen Tissues, Fixed-Formalin Paraffin Embedded Tissues, and Cultured Cells
- Workflow – Spatial Imaging, Spatial Analysis, and Spatial Sequencing
- Application- Diagnostics, Drug Discovery and Development, Translational Research, Single-Cell Analysis, Cell Biology and Others
- End User –Academic and Research Institutions, Biopharmaceutical and Biotechnological Companies, Contract Research Organizations and Other End Users
- North America – U.S., Canada
- Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe
- Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
- Latin America – Brazil, Mexico, and Rest-of-the-Latin America
- Rest-of-the-World
- Increasing Prevalence of Various Types of Genetic Disorders Globally
- Technological Advancements in Sequencing Technologies
- Increasing Research Funding in the Field of Spatial Transcriptomics
- High Capital Requirement Hampering the Expansion of Global Reach
- Lack of Tools for Computational Analysis
- Opportunity (by Product)
- Opportunity (by Technology)
- Expansion into New Research Application such as Spatial Metagenomics
- Expansion into Emerging Markets
NanoString Technologies, Inc., S2 Genomics, Inc., Flagship Biosciences, Inc., Akoya Biosciences, Inc. RareCyte, Inc., IONpath, Inc., Fluidigm Corporation, 10x Genomics, Inc., Visikol, Inc., Miltenyi Biotec, and BioSpyder Technologies
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the global spatial genomics and transcriptomics market?
- What is the potential impact of biotechnological advancement in the diagnostic industry among the end users, such as researchers, pathologists, and laboratory technicians?
- What is the current market demand along with future expected demand for the global spatial genomics and transcriptomics market?
- How have spatial profiling helped cellular imaging and visualization to become a prominent tool for diagnostics in various clinical applications?
- What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
- How is each segment of the market expected to grow during the forecast period from 2020 to 2030 based each on segment?
- product type
- sample type
- workflow
- application
- end user
- region, namely, North America, Europe, Asia-Pacific, Rest-of-the-World (ROW)
- Who are the leading players with significant offerings to the global spatial genomics and transcriptomics market? What is the expected market dominance for each of these leading players?
- Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global spatial genomics and transcriptomics market?
BIS Research healthcare experts have found the spatial genomics and transcriptomics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 23.20% during the forecast period of 2020-2030. The market is driven by certain factors, which include the increasing prevalence of various types of genetic disorders, such as cancer, neurological disorder, and rare diseases, inciting the development of high-resolution multiplex assays and instruments, technological advancements in sequencing technologies, and significant research funding in the field of spatial-based technology for executing R&D exercises.
The market is favored by the development of spatial profiling-based solutions for visualization and analysis of tissue microenvironment, tumor biology, and tissue biomarker. The gradual increase in the prevalence of neurological disorders and rare diseases globally has furthered the spatial genomics and transcriptomics market.
Furthermore, several contract research organizations are focusing on the development of spatial profiling-based services, which enables simultaneous in-situ spatial analysis of multiple biomarkers proteins or more than a hundred mRNAs from single formalin-fixed paraffin-embedded (FFPE) tissue or frozen tissue section.
Within the research report, the market is segmented on the basis of product type, sample type, workflow, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, BioTechne Corporation has been a pioneer in this field and has been a significant competitor in this market.
Other key players in the market are NanoString Technologies, Inc., S2 Genomics, Inc., Flagship Biosciences, Inc., Akoya Biosciences, Inc. RareCyte, Inc., IONpath, Inc., Fluidigm Corporation, 10x Genomics, Inc., Visikol, Inc., Miltenyi Biotec, and BioSpyder Technologies.
On the basis of region, North America holds the largest share of spatial genomics and transcriptomics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Europe region is anticipated to grow at the fastest CAGR of 23.54% during the forecast period 2020-2030.
The market utilizes several technologies, such as barcoding, sequencing, mass cytometry, and microscopy, for the development of instruments and assay for spatial profiling of tissue section to gain an understanding of tissue microenvironment. Each solution offered by the leading players is the combination of next-generation omics tools for application in several clinical areas, such oncology, neurology, immunology, and pathology.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
1.2 Scope of Work
1.3 Key Questions Answered in the Report
2 RESEARCH METHODOLOGY
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling
3 MARKET OVERVIEW
3.1 Spatial Biology: A Next-Generation Tissue Exploration Technology
3.2 Impact of COVID-19 on Spatial Omics Technology
4 MARKET DYNAMICS
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Increasing Prevalence of Various Types of Genetic Disorders, Globally
4.3.2 Technological Advancements in Sequencing Technologies
4.3.3 Increasing Research Funding in the Field of Spatial Transcriptomics
4.4 Market Restraints
4.4.1 High Capital Requirement Hampering the Expansion of Global Reach
4.4.2 Lack of Tools for Computational Analysis
4.5 Market Opportunities
4.5.1 Opportunity (by Product)
4.5.1.1 Services
4.5.2 Opportunity (by Technology)
4.5.2.1 FISSEQ
4.6 Expansion into New Research Application such as Spatial Metagenomics
4.7 Expansion into Emerging Markets
5 COMPETITIVE LANDSCAPE
5.1 Key Strategies and Development
5.1.1 Product Launch and Upgradations
5.1.2 Synergistic Activities
5.1.3 Funding and Expansion
5.1.4 Mergers and Acquisitions
6 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY SAMPLE TYPE)
6.1 Fresh Frozen Tissues
6.2 Fixed Frozen Tissues
6.3 Formalin Fixed Paraffin Embedded (FFPE) tissues
6.4 Cultured Cells
7 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY PRODUCT TYPE)
7.1 Kits and Assays
7.1.1 Sample Preparation Kits
7.1.2 Sample Enrichment Kits
7.2 Instrument
7.2.1 Slide Scanner
7.2.2 Microscopy
7.2.3 Mass Cytometry
7.3 Software
7.4 Services
8 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY WORKFLOW)
8.1 Spatial Imaging
8.1.1 Laser Capture Microdissection (LCM)
8.1.2 Immunohistochemistry (IHC)
8.1.3 Fluorescent In-Situ Hybridization (FISH)
8.1.4 Microscopy
8.1.5 Barcodes
8.1.6 Other
8.2 Spatial Sequencing
8.2.1 Next-Generation Sequencing (NGS)
8.2.2 In-Vivo Transcription
8.2.3 Fluorescent In-Situ Sequencing (FISSEQ)
8.2.4 Microtomy Sequencing
8.2.5 Other
8.3 Spatial Analysis
8.3.1 Data Visualization Tools
8.3.2 Data Analysis Tools
9 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY APPLICATION)
9.1 Diagnostics
9.1.1 Cancer Diagnostics
9.1.2 Neurology Diagnostics
9.1.3 Immunology Diagnostics
9.1.4 Other Diagnostics
9.2 Translation Research
9.3 Drug Discovery and Development
9.4 Single Cell Analysis
9.5 Cell Biology
9.6 Other
10 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY END USER)
10.1 Academic and Research Institutions
10.2 Biopharmaceutical and Biotechnological Companies
10.3 Contract Research Organization
10.4 Other End Users
11 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY REGION)
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 Australia
11.4.4 India
11.4.5 Singapore
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World
12 COMPANY PROFILES
12.1 Fluidigm Corporation
12.1.1 Company Overview
12.1.2 Role of Fluidigm Corporation in Global Spatial Genomics and Transcriptomics Market
12.1.3 Financials
12.1.4 Key Insights About Financial Health of the Company
12.1.5 SWOT Analysis
12.2 10x Genomics, Inc.
12.2.1 Company Overview
12.2.2 Role of 10x Genomics, Inc. in Global Spatial Genomics and Transcriptomics Market
12.2.3 Financials
12.2.4 Key Insights About Financial Health of the Company
12.2.5 SWOT Analysis
12.3 NanoString Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of NanoString Technologies, Inc. in Global Spatial Genomics and Transcriptomics Market
12.3.3 Key Insights About Financial Health of the Company
12.3.4 SWOT Analysis
12.4 Bio-Techne Corporation
12.4.1 Company Overview
12.4.2 Role of Bio-Techne Corporation in Global Spatial Genomics and Transcriptomics Market
12.4.3 Key Insights About Financial Health of the Company
12.4.4 SWOT Analysis
12.5 Flagship Biosciences, Inc.
12.5.1 Company Overview
12.5.2 Role of Flagship Biosciences, Inc. in Global Spatial Genomics and Transcriptomics Market
12.5.3 SWOT Analysis
12.6 Akoya Biosciences, Inc.
12.6.1 Company Overview
12.6.2 Role of Akoya Biosciences, Inc. in Global Spatial Genomics and Transcriptomics Market
12.6.3 SWOT Analysis
12.7 BioSpyder Technologies
12.7.1 Company Overview
12.7.2 Role of BioSpyder Technologies in Global Spatial Genomics and Transcriptomics Market
12.7.3 SWOT Analysis
12.8 S2 Genomics, Inc.
12.8.1 Company Overview
12.8.2 Role of S2 Genomics, Inc. in Global Spatial Genomics and Transcriptomics Market
12.8.3 SWOT Analysis
12.9 IONpath, Inc.
12.9.1 Company Overview
12.9.2 Role of IONpath, Inc. in Global Spatial Genomics and Transcriptomics Market
12.9.3 SWOT Analysis
12.1 Miltenyi Biotec
12.10.1 Company Overview
12.10.2 Role of Miltenyi Biotec in Global Spatial Genomics and Transcriptomics Market
12.10.3 SWOT Analysis
12.11 RareCyte, Inc.
12.11.1 Company Overview
12.11.2 Role of RareCyte, Inc. in Global Spatial Genomics and Transcriptomics Market
12.11.3 SWOT Analysis
12.12 Visikol, Inc.
12.12.1 Company Overview
12.12.2 Role of Visikol, Inc. in Global Spatial Genomics and Transcriptomics Market
12.12.3 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
1.2 Scope of Work
1.3 Key Questions Answered in the Report
2 RESEARCH METHODOLOGY
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling
3 MARKET OVERVIEW
3.1 Spatial Biology: A Next-Generation Tissue Exploration Technology
3.2 Impact of COVID-19 on Spatial Omics Technology
4 MARKET DYNAMICS
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Increasing Prevalence of Various Types of Genetic Disorders, Globally
4.3.2 Technological Advancements in Sequencing Technologies
4.3.3 Increasing Research Funding in the Field of Spatial Transcriptomics
4.4 Market Restraints
4.4.1 High Capital Requirement Hampering the Expansion of Global Reach
4.4.2 Lack of Tools for Computational Analysis
4.5 Market Opportunities
4.5.1 Opportunity (by Product)
4.5.1.1 Services
4.5.2 Opportunity (by Technology)
4.5.2.1 FISSEQ
4.6 Expansion into New Research Application such as Spatial Metagenomics
4.7 Expansion into Emerging Markets
5 COMPETITIVE LANDSCAPE
5.1 Key Strategies and Development
5.1.1 Product Launch and Upgradations
5.1.2 Synergistic Activities
5.1.3 Funding and Expansion
5.1.4 Mergers and Acquisitions
6 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY SAMPLE TYPE)
6.1 Fresh Frozen Tissues
6.2 Fixed Frozen Tissues
6.3 Formalin Fixed Paraffin Embedded (FFPE) tissues
6.4 Cultured Cells
7 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY PRODUCT TYPE)
7.1 Kits and Assays
7.1.1 Sample Preparation Kits
7.1.2 Sample Enrichment Kits
7.2 Instrument
7.2.1 Slide Scanner
7.2.2 Microscopy
7.2.3 Mass Cytometry
7.3 Software
7.4 Services
8 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY WORKFLOW)
8.1 Spatial Imaging
8.1.1 Laser Capture Microdissection (LCM)
8.1.2 Immunohistochemistry (IHC)
8.1.3 Fluorescent In-Situ Hybridization (FISH)
8.1.4 Microscopy
8.1.5 Barcodes
8.1.6 Other
8.2 Spatial Sequencing
8.2.1 Next-Generation Sequencing (NGS)
8.2.2 In-Vivo Transcription
8.2.3 Fluorescent In-Situ Sequencing (FISSEQ)
8.2.4 Microtomy Sequencing
8.2.5 Other
8.3 Spatial Analysis
8.3.1 Data Visualization Tools
8.3.2 Data Analysis Tools
9 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY APPLICATION)
9.1 Diagnostics
9.1.1 Cancer Diagnostics
9.1.2 Neurology Diagnostics
9.1.3 Immunology Diagnostics
9.1.4 Other Diagnostics
9.2 Translation Research
9.3 Drug Discovery and Development
9.4 Single Cell Analysis
9.5 Cell Biology
9.6 Other
10 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY END USER)
10.1 Academic and Research Institutions
10.2 Biopharmaceutical and Biotechnological Companies
10.3 Contract Research Organization
10.4 Other End Users
11 GLOBAL SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET (BY REGION)
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 Australia
11.4.4 India
11.4.5 Singapore
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World
12 COMPANY PROFILES
12.1 Fluidigm Corporation
12.1.1 Company Overview
12.1.2 Role of Fluidigm Corporation in Global Spatial Genomics and Transcriptomics Market
12.1.3 Financials
12.1.4 Key Insights About Financial Health of the Company
12.1.5 SWOT Analysis
12.2 10x Genomics, Inc.
12.2.1 Company Overview
12.2.2 Role of 10x Genomics, Inc. in Global Spatial Genomics and Transcriptomics Market
12.2.3 Financials
12.2.4 Key Insights About Financial Health of the Company
12.2.5 SWOT Analysis
12.3 NanoString Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of NanoString Technologies, Inc. in Global Spatial Genomics and Transcriptomics Market
12.3.3 Key Insights About Financial Health of the Company
12.3.4 SWOT Analysis
12.4 Bio-Techne Corporation
12.4.1 Company Overview
12.4.2 Role of Bio-Techne Corporation in Global Spatial Genomics and Transcriptomics Market
12.4.3 Key Insights About Financial Health of the Company
12.4.4 SWOT Analysis
12.5 Flagship Biosciences, Inc.
12.5.1 Company Overview
12.5.2 Role of Flagship Biosciences, Inc. in Global Spatial Genomics and Transcriptomics Market
12.5.3 SWOT Analysis
12.6 Akoya Biosciences, Inc.
12.6.1 Company Overview
12.6.2 Role of Akoya Biosciences, Inc. in Global Spatial Genomics and Transcriptomics Market
12.6.3 SWOT Analysis
12.7 BioSpyder Technologies
12.7.1 Company Overview
12.7.2 Role of BioSpyder Technologies in Global Spatial Genomics and Transcriptomics Market
12.7.3 SWOT Analysis
12.8 S2 Genomics, Inc.
12.8.1 Company Overview
12.8.2 Role of S2 Genomics, Inc. in Global Spatial Genomics and Transcriptomics Market
12.8.3 SWOT Analysis
12.9 IONpath, Inc.
12.9.1 Company Overview
12.9.2 Role of IONpath, Inc. in Global Spatial Genomics and Transcriptomics Market
12.9.3 SWOT Analysis
12.1 Miltenyi Biotec
12.10.1 Company Overview
12.10.2 Role of Miltenyi Biotec in Global Spatial Genomics and Transcriptomics Market
12.10.3 SWOT Analysis
12.11 RareCyte, Inc.
12.11.1 Company Overview
12.11.2 Role of RareCyte, Inc. in Global Spatial Genomics and Transcriptomics Market
12.11.3 SWOT Analysis
12.12 Visikol, Inc.
12.12.1 Company Overview
12.12.2 Role of Visikol, Inc. in Global Spatial Genomics and Transcriptomics Market
12.12.3 SWOT Analysis
LIST OF TABLES
Table 4.1: Likert Scale
Table 4.2: Impact Analysis of Market Drivers
Table 4.3: Impact Analysis of Market Restraints
Table 4.1: Likert Scale
Table 4.2: Impact Analysis of Market Drivers
Table 4.3: Impact Analysis of Market Restraints
LIST OF FIGURES
Figure 1: Global Neurological Disorder Burden, 2020
Figure 2: Global Health Estimates 2030, Deaths by Age
Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global Spatial Genomics and Transcriptomics Market
Figure 4: Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2020 vs. 2030
Figure 5: Global Spatial Genomics and Transcriptomics Market (by Application), $Million , 2020 vs. 2030
Figure 6: Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million , 2020 vs. 2030
Figure 7: Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2020 vs. 2030
Figure 8: Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2020 vs. 2030
Figure 9: Global Spatial Genomics and Transcriptomics Market Snapshot
Figure 1.1: Global Spatial Genomics and Transcriptomics Market Segments
Figure 2.1: Primary Research Methodology
Figure 2.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.3: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: U.S. Prevalence of Lyme Disease 2009-2018:
Figure 4.2: Global Prevalence Rate of Selected Rare Diseases Per 100,000 People
Figure 4.3: Global Spatial Genomics and Transcriptomics Market (Service), 2020 and 2030
Figure 4.4: Global Spatial Genomics and Transcriptomics Market (FISSEQ), 2020 and 2030
Figure 5.1: Share of Key Developments and Strategies, 2017–2020
Figure 5.2: Product Launch and Upgradation Share (by Company), 2017–2020
Figure 5.3: Synergistic Activities Share (by Company), 2017–2020
Figure 5.4: Funding and Expansion Share (by Company), 2017–2020
Figure 5.5: Merger and Acquisition Share (by Company), 2017–2020
Figure 6.1: Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million, 2019-2030
Figure 6.2: Global Spatial Genomics and Transcriptomics Market (Fresh Frozen Tissues), $Million, 2019-2030
Figure 6.3: Global Spatial Genomics and Transcriptomics Market (Fixed Frozen Tissues), $Million, 2019-2030
Figure 6.4: Global Spatial Genomics and Transcriptomics Market (FFPE Tissues), $Million, 2019-2030
Figure 6.5: Global Spatial Genomics and Transcriptomics Market (Cultured cells), $Million, 2019-2030
Figure 7.1: Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2019-2030
Figure 7.2: Global Spatial Genomics and Transcriptomics Market (Kits and Assays), $Million, 2019-2030
Figure 7.3: Global Spatial Genomics and Transcriptomics Market (Sample Preparation Kits), $Million, 2019-2030
Figure 7.4: Global Spatial Genomics and Transcriptomics Market (Sample Enrichment Kits), $Million, 2019-2030
Figure 7.5: Global Spatial Genomics and Transcriptomics Market (Instrument), $Million, 2019-2030
Figure 7.6: Global Spatial Genomics and Transcriptomics Market (Slide Scanner), $Million, 2019-2030
Figure 7.7: Global Spatial Genomics and Transcriptomics Market (Microscopy), $Million, 2019-2030
Figure 7.8: Global Spatial Genomics and Transcriptomics Market (Mass Cytometry), $Million, 2019-2030
Figure 7.9: Global Spatial Genomics and Transcriptomics Market (Software), $Million, 2019-2030
Figure 7.10: Global Spatial Genomics and Transcriptomics Market (Services), $Million, 2019-2030
Figure 8.1: Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2019-2030
Figure 8.2: Global Spatial Genomics and Transcriptomics Market (Spatial Imaging), $Million, 2019-2030
Figure 8.3: Global Spatial Genomics and Transcriptomics Market (Laser Capture Microdissection), $Million, 2019-2030
Figure 8.4: Global Spatial Genomics and Transcriptomics Market (IHC), $Million, 2019-2030
Figure 8.5: Global Spatial Genomics and Transcriptomics Market ( FISH), $Million, 2019-2030
Figure 8.6: Global Spatial Genomics and Transcriptomics Market (Microscopy), $Million, 2019-2030
Figure 8.7: Global Spatial Genomics and Transcriptomics Market (Barcodes), $Million, 2019-2030
Figure 8.8: Global Spatial Genomics and Transcriptomics Market (Other), $Million, 2019-2030
Figure 8.9: Global Spatial Genomics and Transcriptomics Market (by Spatial Sequencing), $Million, 2019-2030
Figure 8.10: Global Spatial Genomics and Transcriptomics Market (NGS), $Million, 2019-2030
Figure 8.11: Global Spatial Genomics and Transcriptomics Market (In-Vivo Transcription), $Million, 2019-2030
Figure 8.12: Global Spatial Genomics and Transcriptomics Market (FISSEQ), $Million, 2019-2030
Figure 8.13: Global Spatial Genomics and Transcriptomics Market (Microtomy Sequencing), $Million, 2019-2030
Figure 8.14: Global Spatial Genomics and Transcriptomics Market (Other Sequencing), $Million, 2019-2030
Figure 8.15: Global Spatial Genomics and Transcriptomics Market (by Spatial Analysis), $Million, 2019-2030
Figure 8.16: Global Spatial Genomics and Transcriptomics Market (Data Visualization Tool), $Million, 2019-2030
Figure 8.17: Global Spatial Genomics and Transcriptomics Market (Data Analysis Tools), $Million, 2019-2030
Figure 9.1: Global Spatial Genomics and Transcriptomics Market (by Application), $Million, 2019-2030
Figure 9.2: Global Spatial Genomics and Transcriptomics Market (by Diagnostics), $Million, 2019-2030
Figure 9.3: Global Spatial Genomics and Transcriptomics Market (Cancer Diagnostics), $Million, 2019-2030
Figure 9.4: Global Spatial Genomics and Transcriptomics Market (Neurology Diagnostics), $Million, 2019-2030
Figure 9.5: Global Spatial Genomics and Transcriptomics Market (Immunology Diagnostics), $Million, 2019-2030
Figure 9.6: Global Spatial Genomics and Transcriptomics Market (Other Diagnostics), $Million, 2019-2030
Figure 9.7: Global Spatial Genomics and Transcriptomics Market (Translational Research), $Million, 2019-2030
Figure 9.8: Global Spatial Genomics and Transcriptomics Market (Drug Discovery and Development), $Million, 2019-2030
Figure 9.9: Global Spatial Genomics and Transcriptomics Market (Single Cell Analysis), $Million, 2019-2030
Figure 9.10: Global Spatial Genomics and Transcriptomics Market (Cell Biology), $Million, 2019-2030
Figure 9.11: Global Spatial Genomics and Transcriptomics Market (by Others), $Million, 2019-2030
Figure 10.1: Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2019-2030 $Million
Figure 10.2: Global Spatial Genomics and Transcriptomics Market (Academic and Research Institutions), $Million, 2019-2030
Figure 10.3: Global Spatial Genomics and Transcriptomics Market (Biopharmaceutical and Biotech Companies), $Million, 2019-2030
Figure 10.4: Global Spatial Genomics and Transcriptomics Market (Contract Research Organization), $Million, 2019-2030
Figure 10.5: Global Spatial Genomics and Transcriptomics Market (Other End User), $Million, 2019-2030
Figure 11.1: Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2020 and 2030
Figure 11.2: Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2019-2030
Figure 11.3: North America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.4: North America: Market Dynamics
Figure 11.5: North America Spatial Genomics and Transcriptomics Market (by Country), 2019-2030
Figure 11.6: U.S. Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.7: Canada Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.8: Europe Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.9: Europe: Market Dynamics
Figure 11.10: Europe Spatial Genomics and Transcriptomics Market (by Country), $Million, 2019-2030
Figure 11.11: Germany Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.12: France Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.13: U.K. Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.14: Italy Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.15: Spain Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.16: Rest-of-Europe Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.17: Asia-Pacific Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.18: APAC: Market Dynamics
Figure 11.19: APAC Spatial Genomics and Transcriptomics Market (by Country), $Million, 2019-2030
Figure 11.20: China Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.21: Japan Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.22: Australia Spatial Genomics and Transcriptomics Sequencing Market, $Million, 2019-2030
Figure 11.23: India Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.24: Singapore Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.25: RoAPAC Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.26: Latin America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.27: Latin America: Market Dynamics
Figure 11.28: Latin America Spatial Genomics and Transcriptomics Market (by Country), 2019-2030
Figure 11.29: Brazil Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.30: Mexico Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.31: Rest-of-Latin America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.32: RoW Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Fluidigm Corporation: Product Portfolio
Figure 12.3: Fluidigm Corporation: Overall Financials, 2017-2019
Figure 12.4: Fluidigm Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.5: Fluidigm Corporation.: Revenue (by Region), 2017-2019
Figure 12.6: Fluidigm Corporation: R&D Expenditure, 2017-2019
Figure 12.7: Fluidigm Corporation: SWOT Analysis
Figure 12.8: 10x Genomics, Inc.: Product Portfolio
Figure 12.9: 10x Genomics, Inc.: Overall Financials, 2017-2019
Figure 12.10: 10x Genomics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.11: 10x Genomics, Inc.: Revenue (by Region), 2017-2019
Figure 12.12: 10x Genomics, Inc.: R&D Expenditure, 2017-2019
Figure 12.13: 10x Genomics, Inc.: SWOT Analysis
Figure 12.14: NanoString Technologies, Inc.: Product Portfolio
Figure 12.15: NanoString Technologies, Inc.: Overall Financials, (2017-2019)
Figure 12.16: NanoString Technologies, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.17: NanoString Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.18: NanoString Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.19: NanoString Technologies, Inc.: SWOT Analysis
Figure 12.20: Bio-Techne Corporation: Product Portfolio
Figure 12.21: Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 12.22: Bio-Techne Corporation: Revenue (by Business Segment), 2018-2020
Figure 12.23: Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 12.24: Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 12.25: Bio-Techne Corporation: SWOT Analysis
Figure 12.26: Flagship Biosciences, Inc.: Overall Product Portfolio
Figure 12.27: Flagship Biosciences, Inc.: SWOT Analysis
Figure 12.28: Akoya Biosciences, Inc.: Overall Product Portfolio
Figure 12.29: Akoya Biosciences, Inc.: SWOT Analysis
Figure 12.30: BioSpyder Technologies: Overall Product Portfolio
Figure 12.31: BioSpyder Technologies: SWOT Analysis
Figure 12.32: S2 Genomics, Inc.: Overall Product Portfolio
Figure 12.33: S2 Genomics, Inc.: SWOT Analysis
Figure 12.34: IONpath, Inc.: Overall Product Portfolio
Figure 12.35: IONpath, Inc.: SWOT Analysis
Figure 12.36: Miltenyi Biotec: Overall Product Portfolio
Figure 12.37: Miltenyi Biotec: SWOT Analysis
Figure 12.38: RareCyte, Inc.: Overall Product Portfolio
Figure 12.39: RareCyte, Inc.: SWOT Analysis
Figure 12.40: Visikol, Inc.: Overall Product Portfolio
Figure 12.41: Visikol, Inc.: SWOT Analysis
Figure 1: Global Neurological Disorder Burden, 2020
Figure 2: Global Health Estimates 2030, Deaths by Age
Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global Spatial Genomics and Transcriptomics Market
Figure 4: Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2020 vs. 2030
Figure 5: Global Spatial Genomics and Transcriptomics Market (by Application), $Million , 2020 vs. 2030
Figure 6: Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million , 2020 vs. 2030
Figure 7: Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2020 vs. 2030
Figure 8: Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2020 vs. 2030
Figure 9: Global Spatial Genomics and Transcriptomics Market Snapshot
Figure 1.1: Global Spatial Genomics and Transcriptomics Market Segments
Figure 2.1: Primary Research Methodology
Figure 2.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.3: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: U.S. Prevalence of Lyme Disease 2009-2018:
Figure 4.2: Global Prevalence Rate of Selected Rare Diseases Per 100,000 People
Figure 4.3: Global Spatial Genomics and Transcriptomics Market (Service), 2020 and 2030
Figure 4.4: Global Spatial Genomics and Transcriptomics Market (FISSEQ), 2020 and 2030
Figure 5.1: Share of Key Developments and Strategies, 2017–2020
Figure 5.2: Product Launch and Upgradation Share (by Company), 2017–2020
Figure 5.3: Synergistic Activities Share (by Company), 2017–2020
Figure 5.4: Funding and Expansion Share (by Company), 2017–2020
Figure 5.5: Merger and Acquisition Share (by Company), 2017–2020
Figure 6.1: Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million, 2019-2030
Figure 6.2: Global Spatial Genomics and Transcriptomics Market (Fresh Frozen Tissues), $Million, 2019-2030
Figure 6.3: Global Spatial Genomics and Transcriptomics Market (Fixed Frozen Tissues), $Million, 2019-2030
Figure 6.4: Global Spatial Genomics and Transcriptomics Market (FFPE Tissues), $Million, 2019-2030
Figure 6.5: Global Spatial Genomics and Transcriptomics Market (Cultured cells), $Million, 2019-2030
Figure 7.1: Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2019-2030
Figure 7.2: Global Spatial Genomics and Transcriptomics Market (Kits and Assays), $Million, 2019-2030
Figure 7.3: Global Spatial Genomics and Transcriptomics Market (Sample Preparation Kits), $Million, 2019-2030
Figure 7.4: Global Spatial Genomics and Transcriptomics Market (Sample Enrichment Kits), $Million, 2019-2030
Figure 7.5: Global Spatial Genomics and Transcriptomics Market (Instrument), $Million, 2019-2030
Figure 7.6: Global Spatial Genomics and Transcriptomics Market (Slide Scanner), $Million, 2019-2030
Figure 7.7: Global Spatial Genomics and Transcriptomics Market (Microscopy), $Million, 2019-2030
Figure 7.8: Global Spatial Genomics and Transcriptomics Market (Mass Cytometry), $Million, 2019-2030
Figure 7.9: Global Spatial Genomics and Transcriptomics Market (Software), $Million, 2019-2030
Figure 7.10: Global Spatial Genomics and Transcriptomics Market (Services), $Million, 2019-2030
Figure 8.1: Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2019-2030
Figure 8.2: Global Spatial Genomics and Transcriptomics Market (Spatial Imaging), $Million, 2019-2030
Figure 8.3: Global Spatial Genomics and Transcriptomics Market (Laser Capture Microdissection), $Million, 2019-2030
Figure 8.4: Global Spatial Genomics and Transcriptomics Market (IHC), $Million, 2019-2030
Figure 8.5: Global Spatial Genomics and Transcriptomics Market ( FISH), $Million, 2019-2030
Figure 8.6: Global Spatial Genomics and Transcriptomics Market (Microscopy), $Million, 2019-2030
Figure 8.7: Global Spatial Genomics and Transcriptomics Market (Barcodes), $Million, 2019-2030
Figure 8.8: Global Spatial Genomics and Transcriptomics Market (Other), $Million, 2019-2030
Figure 8.9: Global Spatial Genomics and Transcriptomics Market (by Spatial Sequencing), $Million, 2019-2030
Figure 8.10: Global Spatial Genomics and Transcriptomics Market (NGS), $Million, 2019-2030
Figure 8.11: Global Spatial Genomics and Transcriptomics Market (In-Vivo Transcription), $Million, 2019-2030
Figure 8.12: Global Spatial Genomics and Transcriptomics Market (FISSEQ), $Million, 2019-2030
Figure 8.13: Global Spatial Genomics and Transcriptomics Market (Microtomy Sequencing), $Million, 2019-2030
Figure 8.14: Global Spatial Genomics and Transcriptomics Market (Other Sequencing), $Million, 2019-2030
Figure 8.15: Global Spatial Genomics and Transcriptomics Market (by Spatial Analysis), $Million, 2019-2030
Figure 8.16: Global Spatial Genomics and Transcriptomics Market (Data Visualization Tool), $Million, 2019-2030
Figure 8.17: Global Spatial Genomics and Transcriptomics Market (Data Analysis Tools), $Million, 2019-2030
Figure 9.1: Global Spatial Genomics and Transcriptomics Market (by Application), $Million, 2019-2030
Figure 9.2: Global Spatial Genomics and Transcriptomics Market (by Diagnostics), $Million, 2019-2030
Figure 9.3: Global Spatial Genomics and Transcriptomics Market (Cancer Diagnostics), $Million, 2019-2030
Figure 9.4: Global Spatial Genomics and Transcriptomics Market (Neurology Diagnostics), $Million, 2019-2030
Figure 9.5: Global Spatial Genomics and Transcriptomics Market (Immunology Diagnostics), $Million, 2019-2030
Figure 9.6: Global Spatial Genomics and Transcriptomics Market (Other Diagnostics), $Million, 2019-2030
Figure 9.7: Global Spatial Genomics and Transcriptomics Market (Translational Research), $Million, 2019-2030
Figure 9.8: Global Spatial Genomics and Transcriptomics Market (Drug Discovery and Development), $Million, 2019-2030
Figure 9.9: Global Spatial Genomics and Transcriptomics Market (Single Cell Analysis), $Million, 2019-2030
Figure 9.10: Global Spatial Genomics and Transcriptomics Market (Cell Biology), $Million, 2019-2030
Figure 9.11: Global Spatial Genomics and Transcriptomics Market (by Others), $Million, 2019-2030
Figure 10.1: Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2019-2030 $Million
Figure 10.2: Global Spatial Genomics and Transcriptomics Market (Academic and Research Institutions), $Million, 2019-2030
Figure 10.3: Global Spatial Genomics and Transcriptomics Market (Biopharmaceutical and Biotech Companies), $Million, 2019-2030
Figure 10.4: Global Spatial Genomics and Transcriptomics Market (Contract Research Organization), $Million, 2019-2030
Figure 10.5: Global Spatial Genomics and Transcriptomics Market (Other End User), $Million, 2019-2030
Figure 11.1: Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2020 and 2030
Figure 11.2: Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2019-2030
Figure 11.3: North America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.4: North America: Market Dynamics
Figure 11.5: North America Spatial Genomics and Transcriptomics Market (by Country), 2019-2030
Figure 11.6: U.S. Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.7: Canada Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.8: Europe Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.9: Europe: Market Dynamics
Figure 11.10: Europe Spatial Genomics and Transcriptomics Market (by Country), $Million, 2019-2030
Figure 11.11: Germany Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.12: France Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.13: U.K. Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.14: Italy Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.15: Spain Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.16: Rest-of-Europe Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.17: Asia-Pacific Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.18: APAC: Market Dynamics
Figure 11.19: APAC Spatial Genomics and Transcriptomics Market (by Country), $Million, 2019-2030
Figure 11.20: China Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.21: Japan Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.22: Australia Spatial Genomics and Transcriptomics Sequencing Market, $Million, 2019-2030
Figure 11.23: India Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.24: Singapore Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.25: RoAPAC Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.26: Latin America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.27: Latin America: Market Dynamics
Figure 11.28: Latin America Spatial Genomics and Transcriptomics Market (by Country), 2019-2030
Figure 11.29: Brazil Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.30: Mexico Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.31: Rest-of-Latin America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.32: RoW Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Fluidigm Corporation: Product Portfolio
Figure 12.3: Fluidigm Corporation: Overall Financials, 2017-2019
Figure 12.4: Fluidigm Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.5: Fluidigm Corporation.: Revenue (by Region), 2017-2019
Figure 12.6: Fluidigm Corporation: R&D Expenditure, 2017-2019
Figure 12.7: Fluidigm Corporation: SWOT Analysis
Figure 12.8: 10x Genomics, Inc.: Product Portfolio
Figure 12.9: 10x Genomics, Inc.: Overall Financials, 2017-2019
Figure 12.10: 10x Genomics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.11: 10x Genomics, Inc.: Revenue (by Region), 2017-2019
Figure 12.12: 10x Genomics, Inc.: R&D Expenditure, 2017-2019
Figure 12.13: 10x Genomics, Inc.: SWOT Analysis
Figure 12.14: NanoString Technologies, Inc.: Product Portfolio
Figure 12.15: NanoString Technologies, Inc.: Overall Financials, (2017-2019)
Figure 12.16: NanoString Technologies, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.17: NanoString Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.18: NanoString Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.19: NanoString Technologies, Inc.: SWOT Analysis
Figure 12.20: Bio-Techne Corporation: Product Portfolio
Figure 12.21: Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 12.22: Bio-Techne Corporation: Revenue (by Business Segment), 2018-2020
Figure 12.23: Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 12.24: Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 12.25: Bio-Techne Corporation: SWOT Analysis
Figure 12.26: Flagship Biosciences, Inc.: Overall Product Portfolio
Figure 12.27: Flagship Biosciences, Inc.: SWOT Analysis
Figure 12.28: Akoya Biosciences, Inc.: Overall Product Portfolio
Figure 12.29: Akoya Biosciences, Inc.: SWOT Analysis
Figure 12.30: BioSpyder Technologies: Overall Product Portfolio
Figure 12.31: BioSpyder Technologies: SWOT Analysis
Figure 12.32: S2 Genomics, Inc.: Overall Product Portfolio
Figure 12.33: S2 Genomics, Inc.: SWOT Analysis
Figure 12.34: IONpath, Inc.: Overall Product Portfolio
Figure 12.35: IONpath, Inc.: SWOT Analysis
Figure 12.36: Miltenyi Biotec: Overall Product Portfolio
Figure 12.37: Miltenyi Biotec: SWOT Analysis
Figure 12.38: RareCyte, Inc.: Overall Product Portfolio
Figure 12.39: RareCyte, Inc.: SWOT Analysis
Figure 12.40: Visikol, Inc.: Overall Product Portfolio
Figure 12.41: Visikol, Inc.: SWOT Analysis
